Bladder Cancer - Results from #220

REVIEW UroToday

Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations. July 23, 2024

Incidence, Characteristics and Survival Rates of Bladder Cancer after Rectosigmoid Cancer Radiation. July 23, 2024

Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. July 23, 2024

Plasma-Derived Cell-Free DNA as a Biomarker for Early Detection, Prognostication, and Personalized Treatment of Urothelial Carcinoma. July 23, 2024

CircPKN2 promotes ferroptosis in bladder cancer by promoting the ubiquitination of Stearoyl-CoA Desaturase 1. July 22, 2024

Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. July 22, 2024

Survival of Metastatic Urothelial Carcinoma of Urinary Bladder According to Number and Location of Visceral Metastases. July 22, 2024

Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers. July 22, 2024

Adjuvant immune checkpoint inhibitors for urothelial carcinoma: systematic review and Meta-analysis. July 22, 2024

Efficacy of Cretostimogene Grenadenorepvec and Pembrolizumab in BCG-Resistant NMIBC - Expert Commentary July 19, 2024

The current role of pentafecta in the reporting of radical cystectomy outcomes: a scoping review. July 19, 2024

Effect of Bacille Calmette-Guérin for Non-Muscle-Invasive Bladder Cancer After Prostate Radiotherapy. July 19, 2024

What is a Bladder Cancer Molecular Subtype? - Counterpoint. July 19, 2024

IMFINZI® (Durvalumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Event-Free Survival and Overall Survival for Muscle-Invasive Bladder Cancer in NIAGARA Phase III Trial July 18, 2024

Comparison of Robotic vs Open Cystectomy: A Systematic Review. July 18, 2024

Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer. July 18, 2024

The Impact of Dose Reduction of Bacillus Calmette-Guerin on Oncological Outcomes and Toxicity in Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. July 18, 2024

Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer. July 18, 2024

Predictive Value of Computed Tomography Following Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. July 17, 2024

NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors. July 17, 2024

Page 12 of 517